Salomon Manier
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Salomon Manier has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
Guillaume Escure
Department of Hematology, Lille University Hospital, Lille, France; CANTHER, INSERM UMR-S1277 & CNRS UMR9020, Lille University, Lille, France
2 shared publicationsSuman Mitra
CANTHER, INSERM UMR-S1277 & CNRS UMR9020, Lille University, Lille, France
2 shared publicationsThierry Facon
Department of Hematology, Université de Lille, CHU Lille, Lille, France
2 shared publications- Alexia Schwartzmann
LYSARC : Centre Hospitalier Lyon-Sud Batiment 2D, 69495 Pierre-Bénite Cedex, France
1 shared publication - André Baruchel
University Hospital Robert Debré (APHP) and Université Paris Cité, Paris, France
1 shared publication - Artur Jurczyszyn
Plasma Cell Dyscrasia Center, Department of Hematology, Faculty of Medicine, Jagiellonian University Medical College, 31-501 Kraków, Poland
1 shared publication
Latest Publications
- 7 June 2023
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 23 (9) , e297-e306.e1
Predictors of Lenalidomide Refractory Relapse Timing With Newly Diagnosed Multiple Myeloma: A FIRST Trial Subanalysis
- 7 June 2023
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 23 (9) , e297-e306.e1
Predictors of Lenalidomide Refractory Relapse Timing With Newly Diagnosed Multiple Myeloma: A FIRST Trial Subanalysis
- Open Access
- 7 February 2022
- Published by Springer Nature
- p. 127-129
Bridging Chemotherapy: Multiple Myeloma
In the phase 2 KarMMa study, 88% of the patients received bridging therapy with only a 5% response (Munshi et al. 2021). In the CARTITUDE 1 trial, 75% of the patients received bridging therapy, with a reduction in tumour burden observed in 34% of the patients prior to cilta-cel infusion, but no patients achieved a CR or better while on bridging therapy (Madduri et al. 2019). Bridging therapy is recommended for virtually all patients. An exception can be discussed for patients with slowly progressive disease, who may not need to receive bridging therapy after leukapheresis; however, this strategy exposes them to a risk of rapid progression later during the manufacturing period. In the future, with allogeneic CAR-T cells, bridging therapy will likely not be necessary because the time between patient inclusion and CAR-T cell infusion is much reduced.
- 7 February 2022
- Published by Springer Nature
- p. 127-129
Open AccessBridging Chemotherapy: Multiple Myeloma
In the phase 2 KarMMa study, 88% of the patients received bridging therapy with only a 5% response (Munshi et al. 2021). In the CARTITUDE 1 trial, 75% of the patients received bridging therapy, with a reduction in tumour burden observed in 34% of the patients prior to cilta-cel infusion, but no patients achieved a CR or better while on bridging therapy (Madduri et al. 2019). Bridging therapy is recommended for virtually all patients. An exception can be discussed for patients with slowly progressive disease, who may not need to receive bridging therapy after leukapheresis; however, this strategy exposes them to a risk of rapid progression later during the manufacturing period. In the future, with allogeneic CAR-T cells, bridging therapy will likely not be necessary because the time between patient inclusion and CAR-T cell infusion is much reduced.
- 21 January 2022
- Published by Elsevier in Blood Reviews
- Vol. 54, 100929
Current state and next-generation CAR-T cells in multiple myeloma
- 21 January 2022
- Published by Elsevier in Blood Reviews
- Vol. 54, 100929
Current state and next-generation CAR-T cells in multiple myeloma
- 1 October 2021
- Published by Elsevier in Bulletin du Cancer
- Vol. 108 (10) , S143-S154
DESCAR-T, le registre national des patients traités par CAR-T Cells
- 1 October 2021
- Published by Elsevier in Bulletin du Cancer
- Vol. 108 (10) , S143-S154
DESCAR-T, le registre national des patients traités par CAR-T Cells
- 1 October 2021
- Published by Elsevier in Bulletin du Cancer
- Vol. 108 (10) , S205-S212
Myélome multiple et anticorps bispécifiques
- 1 October 2021
- Published by Elsevier in Bulletin du Cancer
- Vol. 108 (10) , S205-S212
Myélome multiple et anticorps bispécifiques
- Open Access
- 5 August 2021
- Published by American Society of Hematology in Blood Advances
- Vol. 5 (15) , 3016-3020
Effective anti-BCMA retreatment in multiple myeloma
The recent emergence of anti–B-cell maturation antigen (BCMA) therapies holds great promise in multiple myeloma (MM). These include chimeric antigen receptor (CAR) T cells, bispecific antibodies, and antibody-drug conjugates. Their development in clinical trials and further approval are changing the strategy for treating MM. Considering that a cure has not been reached, a central question in the coming years will be the possibility of using these therapies sequentially. Here, we report 2 cases of the serial use of anti-BCMA therapies with parallel monitoring of BCMA expression and anti-CAR antibodies. We further discuss recent data from clinical studies that have informed us about the different mechanisms of resistance to anti-BCMA therapies, including antigen escape, BCMA shedding, anti-drug antibodies, T-cell exhaustion, and the emergence of an immunosuppressive microenvironment. This knowledge will be essential to help guide the strategy of serial treatments with anti-BCMA therapies.
- 5 August 2021
- Published by American Society of Hematology in Blood Advances
- Vol. 5 (15) , 3016-3020
Open AccessEffective anti-BCMA retreatment in multiple myeloma
The recent emergence of anti–B-cell maturation antigen (BCMA) therapies holds great promise in multiple myeloma (MM). These include chimeric antigen receptor (CAR) T cells, bispecific antibodies, and antibody-drug conjugates. Their development in clinical trials and further approval are changing the strategy for treating MM. Considering that a cure has not been reached, a central question in the coming years will be the possibility of using these therapies sequentially. Here, we report 2 cases of the serial use of anti-BCMA therapies with parallel monitoring of BCMA expression and anti-CAR antibodies. We further discuss recent data from clinical studies that have informed us about the different mechanisms of resistance to anti-BCMA therapies, including antigen escape, BCMA shedding, anti-drug antibodies, T-cell exhaustion, and the emergence of an immunosuppressive microenvironment. This knowledge will be essential to help guide the strategy of serial treatments with anti-BCMA therapies.
- 12 November 2019
- Published by Springer Nature in Leukemia
- Vol. 34 (2) , 331-332
On the road to molecular prognostication in SMM
- 12 November 2019
- Published by Springer Nature in Leukemia
- Vol. 34 (2) , 331-332
On the road to molecular prognostication in SMM